A multicenter randomized phase III study comparing 6 versus 12 months of trastuzumab in combination with dose dense docetaxel following FE75C [epirubicin + cyclophosphamide + fluoruracil] as adjuvant treatment of women with axillary lymph node positive breast cancer overexpressing HER2 [human epidermal growth factor receptor 2].

Trial Profile

A multicenter randomized phase III study comparing 6 versus 12 months of trastuzumab in combination with dose dense docetaxel following FE75C [epirubicin + cyclophosphamide + fluoruracil] as adjuvant treatment of women with axillary lymph node positive breast cancer overexpressing HER2 [human epidermal growth factor receptor 2].

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jun 2014 Preliminary results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 12 Mar 2012 Planned End Date changed from 1 Dec 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top